Vanguard Global Advisers
EW icon

Vanguard Global Advisers’s Edwards Lifesciences EW Stock Holding History

Vanguard Global Advisers’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112M Sell
1,240,852
-28,674
-2% -$2.4M 0.05% 267
2026
Q1 		$102M Buy
+1,269,526
New +$105M 0.05% 265

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Aristotle Capital Management
Aristotle Capital Management Los Angeles, California $47.7B AUM 13.92% 1-Year Est. Return

Vanguard Global Advisers's EW Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Edwards Lifesciences (EW) stake by 2.3% in Q2 2026, selling an estimated $2.4M and leaving 1,240,852 shares worth $112M. The position accounts for 0.05% of the portfolio, ranked #267.

Vanguard Global Advisers first reported a position in EW in Q1 2026 and has held it in 2 quarters since. 1,259 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Vanguard Global Advisers held 1,240,852 shares of Edwards Lifesciences worth $112M as of Q2 2026.
  • Vanguard Global Advisers sold 28,674 Edwards Lifesciences shares in Q2 2026, an estimated $2.4M.
  • Edwards Lifesciences made up 0.05% of Vanguard Global Advisers's portfolio in Q2 2026, its #267 holding.
  • Vanguard Global Advisers first reported a position in Edwards Lifesciences in Q1 2026 and has held it in 2 quarters since.
  • 1,259 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.